重组人脑利钠肽治疗急性心力衰竭的疗效观察

A Clinical Study of Recombinant Human Brain Natriuretic Peptide on Patients with Acute Decompensated Heart Failure

目的:探讨在监测血清脑钠肽水平下,短期使用注射用重组人脑利钠肽治疗急性心力衰竭或慢性心力衰竭急性发作的临床效果。方法:48例急性心力衰竭患者根据是否使用注射用重组人脑利钠肽分为常规组和注射用重组人脑利钠肽组,对比两组治疗的临床效果和超声心动图情况,并监测BNP水平。结果:治疗7 d后,注射用重组人脑利钠肽组临床有效率明显好于常规组(81.7%vs61.6%,P<0.05),左室射血分数明显高于常规组(51±6)%vs(46±5)%,(P<0.01),且血清脑钠肽水平明显降低(498±209)pg/mL vs(642±318)pg/mL,(P<0.01),血清脑钠肽下降水平和左室射血分数提高水平差异有统计学意义(P<0.05),有效者治疗后左室射血分数提高及血清脑钠肽下降均强于无效者(P<0.01)。结论:在血清脑钠肽指导下短期应用注射用重组人脑利钠肽有助于改善急性心力衰竭患者的临床症状和心功能。

Objective：To observe the clinic efficacy and safety of used recombinant human brain natriuretie peptide （rh-BNP） on patients with acute decompensated heart failure.Methods：48 patients who suffered from acute decompensated heart failure patients were divided into rh-BNP group（n=22）and control group（n=26）.The rh-BNP group received rh-BNP made by China and traditional heart failure treatment; the control group was treated with traditional heart failure treatment.The changes of the clinical efficacy, left ventricular ejection fraction （LVEF） and brain natriuretie peptide test parameters were observed. Results：After 7 days treatment, clinical efficacy improvements were more significant in rh-BNP group compared control group （81.7% vs 61.6,P〈0.05 ）.LVEF were improved in rh-BNP group compared with control group（ （51±6）% vs （46±5）%,P〈0.01 ）.and BNP level were decreased obviously in rh-BNP group than control group（（498±209） pg/ml vs （642±318） pg/ml,P〈0.01 ）, and there had positive relation in BNP decrease and LVEF increased（P〈0.05）.Conclusion： The use of rh-BNP is efficient and safe for acute decompensated heart failure patient.And BNP test can provide a dog marker for diagnosis and prognostic.